Search
biological response modifier; immune factor; immunomodulator; biomodulator
Biologically active substances that affect the immune system.
The role may be stimulatory or inhibitory
Monitor:
- evaluate vaccination status prior to administration of a biological response modifier
- administer recommended vaccinations [2]
Adverse effects:
- not associated with increased risk of malignancy in patients with rheumatoid arthritis
Interactions
drug interactions
Specific
adjuvant
antineoplastic immunomodulator
blinatumomab (Blincyto)
checkpoint inhibitor; immune checkpoint inhibitor; PD-1/PD-L1 inhibitor
dupilumab (Dupixent)
ecallantide (Kalbitor)
GRO-beta(5-73) (Garnocestim)
immunosuppressive agent
insulin-response enhancer
interferon [IFN]-alfa 2a (Roferon-A)
interferon [IFN]-alfa 2b (Intron A)
interferon [IFN]-beta 1A (Avonex)
interferon [IFN]-beta 1B (betaseron, Extavia)
interferon-gamma 1B
leniolisib (Joenja)
mepolizumab (Nucala)
oprelvekin [IL-11] (Neumega)
pharmaceutical interferon
Pharmalgen
secukinumab (Cosentyx)
sipuleucel-T (Provenge)
sublingual allergen extract
tebentafusp-tebn (Kimmtrak)
thymosin
topical immunomodulator (TIM)
TP5 (Timunox, Sintomodulina, Mepentil)
General
pharmaceutical agent
References
- Lopez-Olivo MA et al
Risk of Malignancies in Patients With Rheumatoid Arthritis
Treated With Biologic Therapy: A Meta-analysis
JAMA. 2012;308(9):898-908
PMID: 22948700
http://jama.jamanetwork.com/article.aspx?articleid=1356358
- Ferreira I and Isenberg D.
Vaccines and biologics.
Ann Rheum Dis 2014 Aug; 73:1446
PMID: 24845388
http://ard.bmj.com/content/73/8/1446
- NLM MeSH Browser
http://www.nlm.nih.gov/mesh/meshhome.html